Evaluation of behavioral pain phenotype and optimization of the rat paclitaxel and oxaliplatin models of chemotherapy-induced peripheral neuropathy

Taleen Hanania[1], Elizabeth Dugan[1], Katelyn Buban[1], Jennifer Hagedorn[1], Sarah A. Woller[2], Smriti Iyengar[2] and Mark Urban[1]

[1]PsychoGenics Inc., Paramus, NJ, 07652

[2]Division of Translational Research, National Institutes of Neurological Disorders and Stroke, National Institutes of Health, Rockville, MD 20852

Background

The National Institutes of Health Helping to End Addiction Long-term[SM] Initiative, or NIH HEAL Initiative[SM], Preclinical Screening Platform for Pain (PSPP) program aims to accelerate the discovery and development of new non-opioid, non-addictive pain therapeutics. Toward this goal, PSPP is collaborating with PsychoGenics, Inc. to validate preclinical models and endpoints to enable screening and profiling of assets, including small molecules, biologics, natural products, and devices. Here, we describe the validation of one such effort to optimize the paclitaxel and oxaliplatin models of chemotherapy-induced painful neuropathy in the rat.

Methods

Animals: Adult male and female Sprague Dawley rats (n=10, each sex) were used in these studies. All housing and testing of the animals were in accordance with the Principles of Laboratory Animal Care and the approval of PsychoGenics Inc., Institutional Animal Care and Use Committee in AAALAC-accredited facilities.

Paclitaxel dosing: For the paclitaxel model studies, paclitaxel (Biolyse Pharma) was initially injected at several doses (2 mg/kg, i.p.; 4 mg/kg, i.p.; 2 mg/kg, i.v.) on alternate days (Day 0, 2, 4, 6) to determine the optimal dose and route of administration based on the pharmacokinetic properties of the compound. For the behavioral studies evaluating the effects of paclitaxel on hind paw tactile and cold sensitivity, paclitaxel was injected at a dose of 4 mg/kg, i.p. on four alternate days (Day 0, 2, 4, 6) for a total of 4 injections at a dose volume of 1 ml/kg. Vehicle control rats received the vehicle consisting of 16.7% Ethanol, 16.7% Cremaphor in saline**.**

Oxaliplatin dosing: For the oxaliplatin model studies evaluating effects of oxaliplatin on hind paw tactile and cold sensitivity, oxaliplatin (Biolyse Pharma) was injected 2 days per week (3 day interval) for 4 consecutive weeks at a dose of 3 mg/kg, i.v. and dose volume of 1 ml/kg. Oxaliplatin was prepared in saline vehicle.

Hind paw tactile sensitivity: Hind paw tactile sensitivity was measured by applying von Frey filaments to the plantar hind paw and determining the 50% Withdrawal Threshold using the "up-down" method (Chaplan et al. 1994 J Neurosci Methods 53:55-63).

Hind paw mechanical priming: To examine the effects of mechanical priming of the hind paws on the development of tactile hypersensitivity, rats received mechanical stimulation of both hind paws during Week 2 as follows: 5 consecutive brushes of the plantar surface of the paw from heel to toe using a medium fiber strength, full size toothbrush. 5 consecutive taps of the plantar surface of the paw with the toothbrush; a repeat of the plantar brushing but with only 3 brushes and 3 consecutive applications of the 15 g von Frey filament to the toe area of both hind paws. This procedure was performed once each day for 5 consecutive days (Simmons et al. 2014 J Neurosci Methods 233:50-53).

Hind paw cold sensitivity: An acetone bubble from a 1 ml syringe (~50 µl) was applied to the plantar surface of the hind paw and a withdrawal response or no response was recorded. The acetone was applied 5 times (once every 5 min) to each hind paw (Choi et al. 1994 Pain 59:369-376).

Hind paw cold priming: To examine the effects of cold priming of the hind paws on the development of cold hypersensitivity, rats received acetone stimulation of both hind paws during Week 2. An acetone bubble from a 1 ml syringe (~50 µl) was applied to the plantar surface of the hind paw. The acetone was applied 5 times (once every 5 min) to each hind paw. This was repeated 3 times for a total of 15 applications for each hind paw (total 30 applications each day). This procedure was performed each day for 5 consecutive days.

Paclitaxel Model

Dose	Route	Male			Female		
		Cmax (ng/ml)	Day 1 AUC (ng.h/ml)	Day 1-7 AUC (ng.h/ml)	Cmax (ng/ml)	Day 1 AUC (ng.h/ml)	Day 1-7 AUC (ng.h/ml)
2 mg/kg	IV	N/A	2,160	8,640	N/A	4,468	17,872
2 mg/kg	IP	139	568	2,272	275	1,165	4,660
4 mg/kg	IP	204	1,780	7,120	376	2,207	8,828
6 mg/kg	IP	276	2,898	11,592	494	4,241	16,964

Pharmacokinetics of paclitaxel dosed in rats at 2 mg/kg, i.v., 2 mg/kg, i.p., 4 mg/kg, i.p., and 6 mg/kg, i.p. Rat plasma exposures following dosing of 4 mg/kg, i.p. are consistent with exposures associated with clinical doses of paclitaxel (AUC 6000-8000 ng.h/ml). Rats did not tolerate the 6 mg/kg, i.p. dose

Hind paw tactile and cold allodynia



n=10/group; * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001 Dunnett's test

Effect of Morphine Sulfate



n=10/group; * p<0.05, **** p<0.0001 Dunnett's test

Oxaliplatin Model

Hind paw tactile and cold allodynia



n=10/group; * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001 Dunnett's test

Effect of Morphine Sulfate



n=10/group; * p<0.05, ** p<0.01, **** p<0.0001 Dunnett's test

Conclusion

The validation of models of chemotherapy-induced peripheral neuropathy further highlights efforts within the NIH HEAL Initiative's PSPP program to validate clinically relevant models to evaluate novel assets to accelerate the development of novel non-opioid, non-addictive analgesics.

This project has been funded in whole or in part with Federal funds from the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N95019D00026.

PSPP is currently accepting assets for evaluation

For eligibility and participation inquiries, contact:

Smriti Iyengar, Ph.D.
Program Director
smriti.iyengar@nih.gov

Sarah Woller, Ph.D.
Scientific Project Manager
sarah.woller@nih.gov

For more information about PSPP, visit (or scan the QR):
https://pspp.ninds.nih.gov/

PsychoGenics
Redefining Drug Discovery Through Innovation

NIH National Institute of Neurological Disorders and Stroke

HEAL
NIH - Helping to End Addiction Long-term
https://heal.nih.gov